222 related articles for article (PubMed ID: 29197156)
1. Identification of aggregates in therapeutic formulations of recombinant full-length factor VIII products by sedimentation velocity analytical ultracentrifugation.
Healey JF; Parker ET; Lollar P
J Thromb Haemost; 2018 Feb; 16(2):303-315. PubMed ID: 29197156
[TBL] [Abstract][Full Text] [Related]
2. Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII.
Zakas PM; Healey JF; Smith IW; Lillicrap D; Lollar P
Front Immunol; 2020; 11():150. PubMed ID: 32117290
[TBL] [Abstract][Full Text] [Related]
3. Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.
Delignat S; Peyron I; El Ghazaly M; V Kaveri S; Rohde J; Mueller F; Lacroix-Desmazes S
Cell Immunol; 2018 Sep; 331():22-29. PubMed ID: 29751951
[TBL] [Abstract][Full Text] [Related]
4. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
[TBL] [Abstract][Full Text] [Related]
5. The fraction of recombinant factor VIII:Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studies in vitro.
Ofosu FA; Tse H; Naqvi A; Bhakta H; Song Y
Haemophilia; 2012 Nov; 18(6):917-25. PubMed ID: 22672786
[TBL] [Abstract][Full Text] [Related]
6. Predictive immunogenicity of Refacto AF.
Delignat S; Repessé Y; Gilardin L; Dimitrov JD; Lone YC; Kaveri SV; Lacroix-Desmazes S
Haemophilia; 2014 Jul; 20(4):486-92. PubMed ID: 24372710
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the von Willebrand factor/factor VIII complex produced by a novel purification process.
Ahn JW; Chang ES; Jung YJ; Kim SR; Seong BL; Ha SH
Arch Pharm Res; 2020 Jul; 43(7):714-723. PubMed ID: 32666302
[TBL] [Abstract][Full Text] [Related]
8. Ultracentrifugal analysis of factor VIII and von Willebrand factor in therapeutic preparations.
Aronson DL; Chang P
Vox Sang; 1995; 69(1):8-13. PubMed ID: 7483501
[TBL] [Abstract][Full Text] [Related]
9. Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice.
Pisal DS; Kosloski MP; Middaugh CR; Bankert RB; Balu-Iyer SV
J Pharm Sci; 2012 Jun; 101(6):2055-65. PubMed ID: 22388918
[TBL] [Abstract][Full Text] [Related]
10. Management of bleeding disorders: basic science.
Ofosu FA; Santagostino E; Grancha S; Marco P
Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
[TBL] [Abstract][Full Text] [Related]
11. Conformation of the von Willebrand factor/factor VIII complex in quasi-static flow.
Parker ET; Lollar P
J Biol Chem; 2021; 296():100420. PubMed ID: 33600794
[TBL] [Abstract][Full Text] [Related]
12. Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects.
De Cristofaro R; Sacco M; Lancellotti S; Berruti F; Garagiola I; Valsecchi C; Basso M; Di Stasio E; Peyvandi F
TH Open; 2019 Apr; 3(2):e123-e131. PubMed ID: 31249992
[No Abstract] [Full Text] [Related]
13. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.
Calvez T; Chambost H; d'Oiron R; Dalibard V; Demiguel V; Doncarli A; Gruel Y; Huguenin Y; Lutz P; Rothschild C; Vinciguerra C; Goudemand J;
Haematologica; 2018 Jan; 103(1):179-189. PubMed ID: 29025913
[TBL] [Abstract][Full Text] [Related]
14. Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.
Peyvandi F; Miri S; Garagiola I
Front Immunol; 2020; 11():591878. PubMed ID: 33552050
[TBL] [Abstract][Full Text] [Related]
15. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
16. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison.
Hay CRM; Palmer BP; Chalmers EA; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Collins PW
Haemophilia; 2015 Mar; 21(2):219-226. PubMed ID: 25382829
[TBL] [Abstract][Full Text] [Related]
17. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
[TBL] [Abstract][Full Text] [Related]
18. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII.
Sandberg H; Kannicht C; Stenlund P; Dadaian M; Oswaldsson U; Cordula C; Walter O
Thromb Res; 2012 Nov; 130(5):808-17. PubMed ID: 23010293
[TBL] [Abstract][Full Text] [Related]
19. Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A.
Diego VP; Luu BW; Hofmann M; Dinh LV; Almeida M; Powell JS; Rajalingam R; Peralta JM; Kumar S; Curran JE; Sauna ZE; Kellerman R; Park Y; Key NS; Escobar MA; Huynh H; Verhagen AM; Williams-Blangero S; Lehmann PV; Maraskovsky E; Blangero J; Howard TE
J Thromb Haemost; 2020 Jan; 18(1):201-216. PubMed ID: 31556206
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of recombinant ovine coagulation factor VIII.
Zakas PM; Gangadharan B; Almeida-Porada G; Porada CD; Spencer HT; Doering CB
PLoS One; 2012; 7(11):e49481. PubMed ID: 23152911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
